Antiphospholipid antibodies: Clinical interest and biological diagnosis;Les anticorps 'antiphospholipides': Interet clinique et diagnostic biologique

Annales de Biologie Clinique

Volumn 58, Issue 5, 2000, Pages 557-574

  Arnoux, D ^a   Boutiere, B ^a   Sanmarco, M ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

2 glycoprotein I; Anticardiolipin; Antiphospholipids; Lupus anticoagulant; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; APOLIPOPROTEIN; AUTOANTIBODY; BETA 2-GLYCOPROTEIN I; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; GLYCOPROTEIN; IMMUNOGLOBULIN G; LIPOCORTIN 5; LUPUS ANTICOAGULANT; MEMBRANE PROTEIN; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTHROMBIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; BLOOD CLOTTING TEST; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MALE; REVIEW; SCREENING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; DRUG ANTAGONISM; IMMUNOLOGY;

ADULT; ANNEXIN A5; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; APOLIPOPROTEINS; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION TESTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; PROTHROMBIN; THROMBOSIS;

EID: 0033770583     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Clinical and Serological features of the 'antiphospholipid syndrome'
2. Towards improved criteria for the antiphospholipid syndrome
3. Clinical significance and course of lupus anticoagulants in children
4. Mechanisms of autoantibody-mediated thrombosis
5. Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1 1/2 year-old girl: Report of a case and review of the literature
6. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders
7. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus
8. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant
9. Antiphospholipid antibodies and venous thromboembolism
10. Deep venous thrombosis and lupus anticoagulant: A case-control study
11. Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis
12. Epidemiology of the antiphospholipid syndrome
13. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: A meta-analysis
14. Immunology of the antiphospholipid antibody syndrome
15. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile
16. The sensitivity and specificity of commercial regents for the detection of lupus anticoagulants show marked differences in performance between photo-optical and mechanical coagulometers
17. Monoclonal antibodies against beta-2 glycoprotein I: Use as reference material for lupus anticoagulant tests
18. Guidelines for testing and revised criteria for lupus anticoagulants
19. Criteria for the diagnosis of lupus anticoagulants: An update
20. Evaluation of sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants
21. Many faces of lupus anticoagulants
22. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulant
23. Two different incubation times for the activated partial thromboplastin time (APTT): A new criterion for diagnosis of lupus anticoagulant
24. Optimisation of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin
25. Evaluation of recently described tests for detection of the lupus anticoagulant
26. The tissue thromboplastin inhibition test in the detection of lupus anticoagulants: Importance of a correction factor eliminating the influence of fibrinogen level
27. Antiphospholipid antibodies, haemostatic variables and thrombosis: A survey of 144 patients
28. The Taipan snake venom time: A new test for lupus anticoagulant
29. The textarin/ecarin ratio: A confirmatory test for lupus anticoagulants
30. Time dependance of lupus like anticoagulants
31. Evaluation of different criteria of mixing studies for diagnosis of the lupus anticoagulant
32. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure
33. Effects of instruments on lupus anticoagulant testing
34. Antibodies to factor XII associated with lupus anticoagulant
35. Control of oral anticoagulation in patients with the antiphospholipid syndrome: Influence of the lupus anticoagulant on international normalized ratio
36. Monitoring warfarin therapy in patients with lupus anticoagulants
37. On behalf of the working group on methodologies in haemostasis from GEHT group, France: Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies
38. Factors affecting cardiolipin antibody assays: Modification with polyethylene glycol compound
39. Evaluation of the anticardiolipin antibody test: Report of a standardization workshop held April 4th, 1986
40. On behalf of the participants to the European Forum on the antiphospholipid antibodies (aPL). APL European forum standardization project: Anticardiolipin immunoassay
41. 2-glycoprotein I binding to phospholipid membranes
42. 2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of 'non-self' particles
43. Immunology of the antiphospholipid syndrome: Antibodies, antigens, autoimmune response
44. 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome
45. 2-glycoprotein I
46. 2-glycoprotein I: Preparation and availability to investigators
47. 2-glycoprotein I antibodies
48. Immunology and clinical importance of antiphospholipid antibodies
49. 2-glycoprotein I as an antigen
50. 2-glycoprotein I antibodies in antiphospholipid syndrome: A comparative study with anticardiolipin antibodies
51. 2-glycoprotein I in systemic lupus erythematosus and Primary antiphospholipid antibody syndrome: Clinical correlations in comparison with other antiphospholipid antibody tests
52. Anti-beta2-glycoprotein I antibodies: A marker of antiphospholipid syndrome
53. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss
54. 2-glycoprotein I than with antiphospholipid antibodies
55. Prevalence and kininogen dependence of antiphosphatidylethanolamine antibodies
56. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex
57. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies
58. Evaluation of the clinical and laboratory associations of antiphosphatidylethanolamine antibodies
59. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus
60. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies: 1. Association with thrombosis and vascular cutaneous diseases
61. IgM iso-type Antiphosphatidylethanolamine antibodies (aPEA) in patients with thrombotic events
62. Development of an Elisa for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulant
63. Phospholipid-specific conformational changes in human prothrombin upon binding to procoagulant acidic lipid membranes
64. Anti-prothrombin antibodies and the lupus anticoagulant
65. 2-glycoprotein I antibodies in patients with history of thrombosis
66. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men
67. Anti-annexin V antibody in the sera of patients with habitual fetal loss or preeclampsia
68. Faible prevalence des anticorps anti-annexine V dans le syndrome des antiphospholipides avec pertes foetales
69. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanisms?
70. Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein C deficiencies
71. IgA anticardiolipin antibodies: Relation with other antiphospholipid antibodies and clinical significance